Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.
Malignant Neoplasm of Stomach Stage II
DRUG: Apatinib|DRUG: Paclitaxel-based chemotherapeutic regimens
disease control rate(DCR), 6 months
This trial investigated the efficacy and safety of apatinib plus paclitaxel, as a treatment option for patients with advanced gastric cancer which paclitaxel-resistant.